Home Previous Slide◀︎ Next Slide▶︎ We act with care to create value in the lives of the people we serve We always strive to find new ways to deliver solutions to people living with severe diseases Everyone deserves to live the best life that they can Current Slide Current Slide Current Slide
At UCB, we believe that everyone deserves to live the best life that they can. That’s why - as a global biopharmaceutical leader - we’re focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions. Discover more about us UCBCares® UCBCares® is a personalized service offered by UCB to support people living with a disease and healthcare professionals during their treatment journey with a UCB medicine Contact us here A home for innovation Innovation is a key driver of progress in every aspect of human life including advancing healthcare. Find out more Learn more Empowering women of childbearing age UCB net-zero targets validated by the Science Based Targets initiative Discover the Unbearable Home UCB Stories & Newsroom Story 24 Oct 2025 Multidisciplinary collaboration as the future of patient-centered care Read More Story 17 Sep 2025 Driving progress for people living with dermatological conditions at EADV 2025 Read More Press release 25 Oct 2025 BIMZELX[®] (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained... Read More Press release 14 Oct 2025 Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut... Read More “Every breakthrough we achieve brings us closer to a world where patients can live better, healthier lives.” Sustainability Sustainability is at the heart of everything we do at UCB, guiding our decisions to positively impact society, support communities, and protect the planet for future generations. Learn more UCB ventures UCB Ventures invests in pioneering companies and technologies that have the potential to transform the lives of people living with severe diseases. Learn more
Story 17 Sep 2025 Driving progress for people living with dermatological conditions at EADV 2025 Read More
Press release 25 Oct 2025 BIMZELX[®] (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained... Read More
Press release 14 Oct 2025 Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut... Read More